Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.76 -1.2%	$0.91	$0.45 ▼ $2.26	$46.68M	2.02	437,686 shs	133,131 shs
DWTX Dogwood Therapeutics	$5.48 +1.3%	$5.27	$1.62 ▼ $29.28	$10.47M	1.99	1.97 million shs	178,239 shs
TNYA Tenaya Therapeutics	$0.48 -1.7%	$0.59	$0.39 ▼ $4.96	$42.30M	2.98	2.32 million shs	1.71 million shs
VRCA Verrica Pharmaceuticals	$0.46 +1.0%	$0.54	$0.38 ▼ $11.41	$42.92M	1.68	583,124 shs	119,750 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	-3.23%	-2.31%	-16.89%	-42.94%	-46.15%
DWTX Dogwood Therapeutics	-3.22%	-0.92%	-4.08%	-54.95%	+540,999,900.00%
TNYA Tenaya Therapeutics	-0.17%	+6.20%	-24.81%	-54.00%	-89.36%
VRCA Verrica Pharmaceuticals	-0.95%	-1.77%	+6.17%	-36.07%	-93.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUE Cue Biopharma	4.2229 of 5 stars	3.5	2.0	4.7	3.4	0.8	1.3
DWTX Dogwood Therapeutics	2.2259 of 5 stars	3.5	0.0	0.0	3.4	0.8	0.6
TNYA Tenaya Therapeutics	3.7794 of 5 stars	3.5	4.0	0.0	1.9	5.0	1.3
VRCA Verrica Pharmaceuticals	4.3107 of 5 stars	3.1	2.0	4.7	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	3.00	Buy	$3.00	297.30% Upside
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	82.48% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	1,215.79% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$9.50	1,946.53% Upside

Current Analyst Ratings Breakdown

Latest DWTX, VRCA, TNYA, and CUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/23/2025	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$10.00
4/9/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/31/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/13/2025	TNYA Tenaya Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $6.00
3/12/2025	TNYA Tenaya Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $5.00
3/12/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $9.00
3/12/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/11/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $5.00
2/3/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$9.29M	5.03	N/A	N/A	$0.82 per share	0.92
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$2.05 per share	N/A
VRCA Verrica Pharmaceuticals	$7.57M	5.67	N/A	N/A	$0.47 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$50.73M	-$0.75	N/A	N/A	N/A	-468.02%	-156.38%	-88.07%	5/8/2025 (Estimated)
DWTX Dogwood Therapeutics	-$5.30M	-$11.34	N/A	N/A	N/A	N/A	-217.12%	-172.06%	5/8/2025 (Estimated)
TNYA Tenaya Therapeutics	-$124.08M	-$1.32	N/A	N/A	N/A	N/A	-86.17%	-71.14%	5/13/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$67M	-$1.54	N/A	N/A	N/A	-625.06%	-591.84%	-141.63%	5/12/2025 (Estimated)

Latest DWTX, VRCA, TNYA, and CUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.10	N/A	N/A	N/A	$2.53 million	N/A
5/8/2025	Q1 2025	CUE Cue Biopharma	-$0.15	N/A	N/A	N/A	$0.90 million	N/A
5/8/2025	Q1 2025	DWTX Dogwood Therapeutics	-$1.05	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	DWTX Dogwood Therapeutics	-$1.49	-$6.29	-$4.80	-$6.29	N/A	N/A
3/28/2025	Q4 2024	CUE Cue Biopharma	-$0.14	-$0.13	+$0.01	-$0.13	$1.70 million	$1.80 million
3/17/2025	Q4 2024	TNYA Tenaya Therapeutics	-$0.32	-$0.28	+$0.04	-$0.28	N/A	N/A
3/11/2025	Q4 2024	VRCA Verrica Pharmaceuticals	-$0.25	-$0.24	+$0.01	-$0.24	$1.30 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	0.05	2.22	2.22
DWTX Dogwood Therapeutics	N/A	1.71	1.71
TNYA Tenaya Therapeutics	N/A	5.27	5.27
VRCA Verrica Pharmaceuticals	N/A	1.34	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
DWTX Dogwood Therapeutics	9.05%
TNYA Tenaya Therapeutics	90.54%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	12.26%
DWTX Dogwood Therapeutics	12.20%
TNYA Tenaya Therapeutics	32.76%
VRCA Verrica Pharmaceuticals	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	61.82 million	55.58 million	Optionable
DWTX Dogwood Therapeutics	5	1.91 million	1.17 million	N/A
TNYA Tenaya Therapeutics	110	87.58 million	53.27 million	Optionable
VRCA Verrica Pharmaceuticals	40	92.46 million	26.18 million	Optionable

DWTX, VRCA, TNYA, and CUE Headlines

Recent News About These Companies

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30 at 8:00 AM | globenewswire.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Earns Hold Rating from Needham & Company LLC

April 11, 2025 | marketbeat.com

HC Wainwright Has Optimistic Outlook of VRCA FY2028 Earnings

April 11, 2025 | marketbeat.com

HC Wainwright Reaffirms Neutral Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)

April 10, 2025 | marketbeat.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 10, 2025 | aaii.com

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

RBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)

April 5, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors

April 4, 2025 | msn.com

Verrica Pharmaceuticals Appoints Dr. Corcoran as Director

April 2, 2025 | tipranks.com

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

April 2, 2025 | globenewswire.com

Verrica Pharmaceuticals to Present at Needham Healthcare Conference

April 2, 2025 | msn.com

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now

April 1, 2025 | zacks.com

Harmony, Lungpacer, Verrica and Arbutus make C-suite hires

April 1, 2025 | bizjournals.com

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer

March 28, 2025 | msn.com

Verrica Pharmaceuticals appoints Rosenberg as CMO

March 26, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

March 26, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, VRCA, TNYA, and CUE Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.76 -0.01 (-1.24%)

As of 04:00 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Dogwood Therapeutics NASDAQ:DWTX

$5.48 +0.07 (+1.29%)

As of 04:00 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Tenaya Therapeutics NASDAQ:TNYA

$0.48 -0.01 (-1.66%)

As of 04:00 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.46 +0.00 (+0.98%)

As of 04:00 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time